RecruitingPlaque Psoriasis

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Eligible age

18–79 yrs

Accepts

All genders

Locations

14 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Sponsor: Oruka Therapeutics, Inc.

You may qualify if…

✓ 1. Participants ≥ 18 and \< 80 years of age at the time of consent
✓ 2. Have a diagnosis of plaque psoriasis for \> 6 months
✓ 3. Have moderate-to-severe chronic plaque psoriasis defined as:
✓ 1. BSA ≥ 10%, and
✓ 2. PASI ≥ 12, and
✓ 3. IGA score of ≥ 3 on a 5-point scale
✓ 4. Candidate for systemic therapy or phototherapy
✓ 5. Women of childbearing potential must have a negative pregnancy test

You may not qualify if…

✕ 1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis)
✕ 2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
✕ 3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
✕ 4. A known hypersensitivity to any components of the ORKA-002 drug product
✕ 5. Women who are breastfeeding or plan to breastfeed during the study